Meet our team

A medical doctor who also completed an MBA, an effective manager. Organizer of business models and company structures – experienced in building and developing companies as well as leading corporate restructuring processes. Former director and motivator of large companies and teams. Recognized as a leader in the Polish pharmaceutical industry. Member of the Supervisory Board of American Heart of Poland SA and President of WSiP SA. Previously, President of AstraZeneca Sp. z o.o., President of Fournier Polska Sp. z o.o., Sales Director at Pfizer Polska Sp. z o.o., Sales Director and Marketing Director at MSD Poland – also involved in clinical research.

A well-known investor focused on companies in the medical and biotechnology sectors. He has extensive professional experience in the healthcare industry. Founder of Prosper S.A., which is part of the NEUCA S.A. Capital Group – a leader in the pharmaceutical distribution market in Poland. Member of the supervisory boards of companies listed on the Warsaw Stock Exchange: NEUCA, Selvita, and Braster. He is also involved in Venture Capital funds: Inovo and Experior. He holds a PhD in technical sciences and is a graduate of the Warsaw University of Technology.

Co-Founder of CirCap and Capmont. Łukasz spent 9 years with Advent International, where, working in the Warsaw and London offices, he allocated over €650 million in investments. Previously, he served as Vice President at StepStone Group, and prior to that, as an Associate at Citi Private Equity. At Citi, he was responsible for managing and monitoring the $3.7 billion EMEA portfolio and preparing investment recommendations for various private equity and debt products.

Łukasz holds a BA from Rotterdam School of Management / Erasmus University and an MSc in Economics (with distinction) from the London School of Economics.

Throughout his career, he has participated in 19 transactions, including 11 private equity investments with an average return of 9.3x MoIC (Multiple of Invested Capital), involving companies such as InPost, Corialis, Partner in Pet Food, Visma, Valentino Fashion Group, Aster City, and Ultimo.

Academic Lecturer and Manager in Finance and Banking.
Dr. Rafał Płókarz is an experienced manager with a long career in leading banks in Poland (mBank; Bank BPH) and abroad (Edmond de Rothschild). He has also served on supervisory boards and audit committees for a number of capital market companies.

Since 2000, he has been an academic lecturer at top business universities, including Kozminski University in Warsaw, WSB Merito University in Toruń, and the Faculty of Management at the University of Warsaw. He is the author of dozens of scientific publications, including five academic-scientific books in the field of finance.

Dr. Tomasz H. Zastawny is a manager and expert in the life sciences sector with over 25 years of experience gained at international pharmaceutical, biotechnology, and medical companies. He specializes in strategic management, the development of innovative therapies, mergers and acquisitions, and the commercialization of new products in global markets.

He has held top management positions in international organizations active in the fields of clinical research, drug development, and biotechnology. He is currently the CEO of Armora Bio. Previously, he held positions including Chief Drug Development Officer at Parexel, Senior Vice President at Rakuten Medical, and Chief Development Officer at Adial Pharma. Throughout his career, he has led projects related to the development and global market launch of innovative therapies and medical devices.

He also has experience in venture capital investments, gained, among other roles, as a Partner and Chief Scientific Officer at Quark Venture. He actively participates in the development of technology and medical companies, serving in supervisory and advisory roles at entities operating in international markets.

Tomasz H. Zastawny, Ph.D., earned his postdoctoral degree from the Polish Academy of Sciences and his Ph.D. from Nicolaus Copernicus University. He has also completed executive education programs at Harvard Business School, including the Corporate Director Program, the Certificate in Finance, and the Strategy Execution Program. He is the author of over 80 scientific publications and a co-author of books on clinical trials and biopharmaceutical development.

Jakub Tatak is a financial manager with approximately 20 years of experience in corporate financial management. He has been with the LUX MED Group since 2008, where he participated in the integration and development of one of the largest private medical groups in Poland. Since 2018, he has served as a member of the LUX MED Management Board, responsible for finance, including mergers and acquisitions, financial planning and controlling, liquidity management, accounting and taxes, investments, and procurement.

From 2014 to 2018, he served as a member of the management board and chief financial officer of Carolina Medical Center, a subsidiary of the LUX MED Group. Previously, he held management positions in finance and auditing at PolCard, a subsidiary of First Data Corporation.

He also has experience in corporate governance as a member of the supervisory boards of LUX MED Group subsidiaries, including companies listed on the Warsaw Stock Exchange.

He is a graduate of the Faculty of Management at the Academy of Commerce and Law in Warsaw. He has also completed numerous executive development programs offered by international educational institutions.